Molecular Formula | C6H12F2N2O2 |
Molar Mass | 182.17 |
Density | 1.1800 (estimate) |
Melting Point | 138 °C |
Boling Point | 347.0±42.0 °C(Predicted) |
Flash Point | 163.7°C |
Solubility | H2O: >10mg/mL, soluble |
Vapor Presure | 9.72E-06mmHg at 25°C |
Appearance | solid |
Color | white |
pKa | 1.22±0.44(Predicted) |
Storage Condition | Store at 0°C |
Refractive Index | 1.462 |
In vivo study | Eflornithine is the only new molecule registered for the treatment of human African trypanosomiasis over the last 50 years. It is the drug used mainly as a back-up for melarsoprol refractory Trypanosoma brucei gambiense cases. In subjects with excessive, unwanted facial hair, eflornithine 15% cream is superior to placebo in reducing hair growth. After 24 weeks' treatment, 58% of eflornithine and 34% of placebo subjects have at least some improvement in facial hirsutism. The hair growth inhibitory activity of eflornithine is significantly enhanced when the eflornithine cream is applied onto a mouse skin area pretreated with microneedles. Treatment of coarctation hypertensive rats with eflornithine results in a normalization of the contractile intensity to KCI and norepinephrine and relaxations to acetylcholine by 14 days of hypertension. |
WGK Germany | 3 |